GPhA Announces Resignation of Regulatory Sciences VP Gordon Johnston
Johnston to Serve as Senior Advisor for Regulatory Sciences
WASHINGTON, D.C., MARCH 21, 2011 – The Generic Pharmaceutical Association (GPhA) today announced that Gordon Johnston will resign, effective April 1, 2011, as Vice President of Regulatory Sciences, a position he has held since 2003. Mr. Johnston will serve as Senior Advisor for Regulatory Sciences at GPhA beginning in April.
“Gordon’s commitment and contributions to the generic pharmaceutical industry over the years cannot be overstated. He has helped increase communication and interaction with the FDA, implemented many programs that have helped our association play a critical role in quality, and has been instrumental in preparing GPhA to participate in the upcoming generic user fee negotiations,” said Paul Bisaro, Chairman of the GPhA Board of Directors and President & CEO of Watson Pharmaceuticals, Inc. “It is impossible to adequately express our thanks for his tireless support of the generic industry and his outstanding service, not only for the Association but also during the years he served in the FDA Office of Generic Drugs,” Mr. Bisaro added.
Mr. Johnston has more than 25 years of experience in the pharmaceutical industry, beginning with the U.S. Public Health Service, where he served in a number of pharmacist and health care management positions. In 1987, he was assigned to the Food and Drug Administration and, in 1994, was promoted to be Deputy Director of the FDA’s Office of Generic Drugs (OGD). The OGD is responsible for the review and approval of all generic drugs in the U.S. Mr. Johnston was a key member of the FDA team that developed and put into practice the regulations implementing the 1984 Hatch-Waxman amendments.
Following his retirement from the FDA in 1999, Mr. Johnston served as a consultant to the pharmaceutical industry. While at GPhA he has been the primary industry spokesperson on science and regulatory matters that impact the generic drug industry. He is active in current health reform issues including biogeneric and generic user fee discussions with the FDA.